These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22803602)

  • 1. Pharmacokinetic evaluation of armodafinil for the treatment of bipolar depression.
    Niemegeers P; Maudens KE; Morrens M; Patteet L; Joos L; Neels H; Sabbe BG
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1189-97. PubMed ID: 22803602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Armodafinil in the treatment of excessive sleepiness.
    Bogan RK
    Expert Opin Pharmacother; 2010 Apr; 11(6):993-1002. PubMed ID: 20307223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies.
    Darwish M; Kirby M; Hellriegel ET; Yang R; Robertson P
    Clin Drug Investig; 2009; 29(2):87-100. PubMed ID: 19133704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat.
    Wisor JP; Dement WC; Aimone L; Williams M; Bozyczko-Coyne D
    Pharmacol Biochem Behav; 2006 Nov; 85(3):492-9. PubMed ID: 17134745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression.
    Krystal AD; Harsh JR; Yang R; Rippon GA; Lankford DA
    J Clin Psychiatry; 2010 Jan; 71(1):32-40. PubMed ID: 20051221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss.
    Dinges DF; Arora S; Darwish M; Niebler GE
    Curr Med Res Opin; 2006 Jan; 22(1):159-67. PubMed ID: 16393442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Armodafinil for excessive daytime sleepiness.
    Nishino S; Okuro M
    Drugs Today (Barc); 2008 Jun; 44(6):395-414. PubMed ID: 18596995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic exposure to armodafinil and its tolerability in healthy elderly versus young men: an open-label, multiple-dose, parallel-group study.
    Darwish M; Kirby M; Hellriegel ET; Yang R; Robertson P
    Drugs Aging; 2011 Feb; 28(2):139-50. PubMed ID: 21275439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulants for treating bipolar disorder: pro and con.
    Grunze H
    Harv Rev Psychiatry; 2014; 22(6):358-62. PubMed ID: 25377610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study.
    Darwish M; Kirby M; D'Andrea DM; Yang R; Hellriegel ET; Robertson P
    Clin Ther; 2010 Nov; 32(12):2074-87. PubMed ID: 21118743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
    Roth T; White D; Schmidt-Nowara W; Wesnes KA; Niebler G; Arora S; Black J
    Clin Ther; 2006 May; 28(5):689-706. PubMed ID: 16861091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites.
    Willavize S; Fiedler-Kelly J; Ludwig E; Guan L
    J Clin Pharmacol; 2017 Feb; 57(2):255-265. PubMed ID: 27436172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression.
    Frye MA; Grunze H; Suppes T; McElroy SL; Keck PE; Walden J; Leverich GS; Altshuler LL; Nakelsky S; Hwang S; Mintz J; Post RM
    Am J Psychiatry; 2007 Aug; 164(8):1242-9. PubMed ID: 17671288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Armodafinil and modafinil in patients with excessive sleepiness associated with shift work disorder: a pharmacokinetic/pharmacodynamic model for predicting and comparing their concentration-effect relationships.
    Darwish M; Bond M; Ezzet F
    J Clin Pharmacol; 2012 Sep; 52(9):1328-42. PubMed ID: 22039290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies.
    Darwish M; Kirby M; Hellriegel ET; Robertson P
    Clin Drug Investig; 2009; 29(9):613-23. PubMed ID: 19663523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Armodafinil: a new treatment for excessive sleepiness.
    Lankford DA
    Expert Opin Investig Drugs; 2008 Apr; 17(4):565-73. PubMed ID: 18363520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome.
    Hirshkowitz M; Black JE; Wesnes K; Niebler G; Arora S; Roth T
    Respir Med; 2007 Mar; 101(3):616-27. PubMed ID: 16908126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults.
    Darwish M; Bond M; Yang R; Hellriegel ET; Robertson P
    Clin Ther; 2015 Feb; 37(2):325-37. PubMed ID: 25438721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy.
    Harsh JR; Hayduk R; Rosenberg R; Wesnes KA; Walsh JK; Arora S; Niebler GE; Roth T
    Curr Med Res Opin; 2006 Apr; 22(4):761-74. PubMed ID: 16684437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period.
    Schwartz JR; Khan A; McCall WV; Weintraub J; Tiller J
    J Clin Sleep Med; 2010 Oct; 6(5):450-7. PubMed ID: 20957845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.